Device Trial Radar · NCT07110454
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Dec 23, 2025
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- Epiminder America, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 7, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research is to address the challenges of correctly monitoring, managing, and diagnosing epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This research is being done to understand how the Minder System helps physicians make decisions about participant's epilepsy treatment after an actionable event. The Minder System was granted De Novo classification by the U.S. Food and Drug Administration (FDA) and is not investigational. Participants that have completed the DETECT study and received the Minder System previously will consent to join this long-term follow-up observational study. The study will collect information about general wellbeing, use of healthcare services, and experience using the Minder data over time to support long-term epilepsy care. All participants will continue to be followed by their treating physician and undergo assessments and visits every six (6) months until two (2) years after receiving the Minder device.
Conditions
- Epilepsy
- Epilepsy (Treatment Refractory)
Interventions
Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)Device
The Minder System consists of an implanted device containing an electrode lead and telemetry unit. The electrode lead contains four electrodes that are placed under the patient's scalp to record electrical activity (EEGs) from both sides of the brain. The electrode lead is connected to the telemetry until that continuously transmits these signals to the external Minder devices to remotely show EEGs for clinician review.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the Minder System to aid in treatment following an actionable event by comparing change using the Patient Global Impression scale (PGIC) from baseline to follow-up.Time frame: 2 years
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
UAB Epilepsy Center
Birmingham, Alabama · Recruiting
Mayo Clinic - Arizona
Phoenix, Arizona · Recruiting
Stanford
Palo Alto, California · Recruiting
18 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.